Obesity Care Still Relies on Blunt Tools While Risk Remains Uneven
Obesity has become a global clinical problem not because excess adiposity is new, but because the biology behind it is far more heterogeneous than routine practice often assumes. A patient can meet the same anthropometric threshold as another and yet carry a very different burden of cardiometabolic injury, inflammatory activity, sleep-disordered breathing, or cancer risk. BMI and similar measurements remain widely used because they are easy to obtain, but they do not capture the underlying genotype, phenotype, or endotype that shape prognosis and response to therapy.
This mismatch matters at the bedside. A single label can obscure wide variation in insulin resistance, visceral fat distribution, ectopic fat accumulation, appetite regulation, and adipose tissue dysfunction. When those mechanisms differ, the downstream complications differ as well, which helps explain why cardiovascular disease and type 2 diabetes continue to drive much of the morbidity and mortality linked to obesity.
Cardiometabolic Complications Drive the Highest Clinical Burden
The strongest signal in obesity care is not the scale itself but the complications that accumulate around it. Cardiovascular disease and diabetes sit at the center of obesity-related harm, while hypertension, dyslipidaemia, obstructive sleep apnoea, and obesity-related cancers add additional clinical strain. These conditions do not simply coexist; they often reinforce one another through shared inflammatory, metabolic, and hemodynamic pathways.
Excess adipose tissue can promote chronic low-grade inflammation, insulin resistance, endothelial dysfunction, and adverse lipid handling. In practical terms, this means the same excess weight can manifest as silent vascular disease in one patient, worsening glycaemic control in another, and sleep disruption or malignant risk in a third. A diagnostic strategy that treats all of these patients as biologically interchangeable is too crude for the level of risk involved.
One-size-fits-all obesity care misses the biology.
Anthropometric Measurement Alone Cannot Stratify the Full Spectrum of Disease
Routine clinical assessment still depends heavily on anthropometric measures, but these tools were never designed to define mechanism. They can estimate adiposity, yet they cannot distinguish metabolically healthy from metabolically unhealthy obesity, nor can they identify the patient whose central adiposity carries disproportionate cardiovascular risk. They also fail to show which biological pathway is dominant: impaired satiety signalling, altered energy expenditure, insulin resistance, inflammatory activation, or differences in adipose tissue function.
This limitation has direct therapeutic consequences. Metabolic surgery and pharmacological treatment can be highly effective, but outcomes are unlikely to be uniform across a population defined only by weight-related thresholds. The degree of benefit may depend on the specific biology driving weight gain and organ injury. Without better stratification, clinicians risk offering the same intervention to patients whose disease mechanisms, and therefore treatment needs, are not the same.
Precision Medicine Offers a More Useful Framework for Obesity
A more individualized approach begins with the assumption that obesity is not one disease but a spectrum of related disorders. Precision medicine aims to separate that spectrum into clinically meaningful subgroups using multi-omics, biomarkers, and advanced diagnostic technologies. Genomic, transcriptomic, proteomic, metabolomic, and microbiome-based data can each reveal different layers of biology, and together they may identify why one patient develops severe complications while another does not.
Biomarkers could help move obesity management away from static measurement and toward dynamic risk assessment. In theory, they may identify inflammatory burden, metabolic stress, tissue dysfunction, or treatment responsiveness before those processes become clinically obvious. Advanced diagnostic technologies may further refine this picture by improving the ability to detect relevant phenotypes rather than relying on weight alone.
The promise here is practical, not abstract. If a clinician can better distinguish the dominant pathophysiology in a given patient, treatment selection becomes more rational. Pharmacological therapy, metabolic surgery, and long-term prevention strategies could all be better matched to biology instead of applied broadly under a single diagnostic label.
Better Stratification Could Improve Both Prevention and Treatment
The review places clear weight on patient stratification because effective prevention and treatment depend on knowing which patients are most likely to progress to complications. A person with obesity who already shows cardiometabolic injury is not the same as a person with the same body size but fewer metabolic abnormalities. Their near-term risk differs, and so may their response to intervention.
This is especially relevant for the prevention of downstream disease. Earlier identification of high-risk subgroups could support more aggressive intervention before cardiovascular disease, diabetes, or other complications become entrenched. It could also reduce the trial-and-error pattern that still shapes much of obesity treatment, where effectiveness is often judged late, after complications have already advanced.
The clinical goal is not merely to lower weight. It is to reduce organ injury, improve function, and prevent the diseases that account for the greatest share of harm.
Future Obesity Care Depends on Biology, Not Body Size Alone
The review makes a strong case that obesity management is moving toward a more evidence-based and patient-centered model. That shift depends on integrating diagnostic tools that reflect the heterogeneity of the condition rather than collapsing it into a single number. Multi-omics, biomarkers, and precision diagnostics are not replacements for routine clinical assessment, but they may fill the gap left by anthropometry alone.
For now, the central problem remains unchanged: obesity is common, clinically diverse, and tightly linked to high-burden complications, yet routine care still stratifies many patients with tools that cannot fully explain their risk. A framework built on biology rather than body size would allow clinicians to better identify who needs early intervention, who is most likely to benefit from surgery or medication, and who carries the highest burden of cardiometabolic and malignant disease.
The remaining challenge is implementation. Precision approaches will need validation, access, and clinical pathways that can translate complex molecular data into decisions that work in everyday practice.